TriSalus Life Sciences Inc
TLSI
Get informed when a big investor buys or sells
+ FollowMarket Cap$324.5M
Close$
$-8.19
269.6% downside
Current Fair Value
269.6% downsideOvervalued by 269.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $324.50 Million |
|---|---|
| Enterprise Value | $312.64 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.84 |
| Beta | 0.43 |
| Outstanding Shares | 58,296,711 |
Return
| Return on Equity | -895.80% |
|---|---|
| Return on Assets | -93.96% |
| Return on Invested Capital | -55.68% |
Valuation & Multiples
| P/E Ratio | -4.05 |
|---|---|
| PEG | -37.37 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.94 |
| Enterprise Value to EBIT | -10.95 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 5.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$10.27 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$14.02 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 40.46%▲ 16.11% |
|---|---|
| Total Invested | $83.42M▲ 4.76% |
| Investors Holding | 85▲ 21.00% |
ESG Score
No data